| 1 |
33174519 | p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. | 2022 Apr |
3 |
| 2 |
33280593 | Investigating the Impact of Different Acrylamide (Electrophilic Warhead) on Osimertinib's Pharmacological Spectrum by Molecular Mechanic and Quantum Mechanic Approach. | 2022 |
2 |
| 3 |
34074804 | Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations. | 2022 Jan 1 |
1 |
| 4 |
34240438 | Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report. | 2022 Feb |
2 |
| 5 |
34261918 | Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases. | 2022 Jan 1 |
3 |
| 6 |
34263613 | Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: case report. | 2022 Apr |
3 |
| 7 |
34309914 | Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis. | 2022 Jan |
1 |
| 8 |
34323489 | Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. | 2022 Jan 27 |
5 |
| 9 |
34331582 | The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. | 2022 Jun |
1 |
| 10 |
34344199 | Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. | 2022 Apr |
2 |
| 11 |
34459459 | Systematic analysis of the potential off-target activities of osimertinib by computational target fishing. | 2022 Jan 1 |
2 |
| 12 |
34486539 | Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed. | 2022 Jan 1 |
2 |
| 13 |
34520433 | A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance. | 2022 Jan 1 |
2 |
| 14 |
34544302 | Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer. | 2022 Jan |
1 |
| 15 |
34599981 | PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression. | 2022 Jan |
2 |
| 16 |
34605320 | Elevated serum creatine kinase levels due to osimertinib: A case report and review of the literature. | 2022 Mar |
2 |
| 17 |
34643820 | Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). | 2022 Jan |
5 |
| 18 |
34648945 | Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. | 2022 Feb |
1 |
| 19 |
34669648 | Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer. | 2022 Jan 1 |
1 |
| 20 |
34706132 | Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells. | 2022 Jan |
1 |
| 21 |
34740861 | Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. | 2022 Mar |
1 |
| 22 |
34758637 | First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. | 2022 Jan |
1 |
| 23 |
34794818 | Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation. | 2022 Jan 15 |
1 |
| 24 |
34807331 | First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. | 2022 Apr |
6 |
| 25 |
34839016 | A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. | 2022 Feb |
4 |
| 26 |
34844838 | Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. | 2022 Jan |
1 |
| 27 |
34861243 | Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. | 2022 Jan |
1 |
| 28 |
34865963 | Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. | 2022 Jan |
3 |
| 29 |
34887192 | Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). | 2022 May |
2 |
| 30 |
34894319 | Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice. | 2022 Jan |
1 |
| 31 |
34911336 | MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. | 2022 Feb |
2 |
| 32 |
34918542 | Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary. | 2022 Feb |
1 |
| 33 |
34958168 | Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib. | 2022 Feb |
2 |
| 34 |
34962076 | Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions. | 2022 Feb |
1 |
| 35 |
34969538 | [Pulmonary manifestations induced by osimertinib]. | 2022 Jan |
2 |
| 36 |
34974477 | Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer. | 2022 Mar 1 |
2 |
| 37 |
34979367 | Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors. | 2022 May |
1 |
| 38 |
34983748 | Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study. | 2022 Jan 4 |
3 |
| 39 |
34985966 | Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. | 2022 Feb 20 |
1 |
| 40 |
35005653 | Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report. | 2022 Jan |
1 |
| 41 |
35005656 | EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report. | 2022 Jan |
2 |
| 42 |
35023208 | Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study. | 2022 May |
1 |
| 43 |
35037771 | Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma. | 2022 Jun |
4 |
| 44 |
35038824 | Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion. | 2022 Jan 17 |
3 |
| 45 |
35044639 | Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients. | 2022 Feb |
4 |
| 46 |
35045945 | Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer. | 2022 Jun |
3 |
| 47 |
35049698 | Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. | 2022 Jan 9 |
1 |
| 48 |
35066105 | Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. | 2022 Apr |
2 |
| 49 |
35076999 | First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations. | 2022 Mar |
4 |
| 50 |
35078784 | Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer. | 2022 Apr 1 |
4 |